<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="article-commentary" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Int. J. Public Health</journal-id>
<journal-title>International Journal of Public Health</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Int. J. Public Health</abbrev-journal-title>
<issn pub-type="epub">1661-8564</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1608617</article-id>
<article-id pub-id-type="doi">10.3389/ijph.2025.1608617</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Public Health Archive</subject>
<subj-group>
<subject>Commentary</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Introducing Preference Epidemiology: Improving Patient-Centered Approaches in Health Decision-Making</article-title>
<alt-title alt-title-type="left-running-head">Spitale et al.</alt-title>
<alt-title alt-title-type="right-running-head">Introducing Preference Epidemiology</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Spitale</surname>
<given-names>Giovanni</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1575398/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Germani</surname>
<given-names>Federico</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1886068/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Biller-Andorno</surname>
<given-names>Nikola</given-names>
</name>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1432090/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Institute of Biomedical Ethics and History of Medicine</institution>, <institution>University of Zurich</institution>, <addr-line>Zurich</addr-line>, <country>Switzerland</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Center for Medical Ethics</institution>, <institution>University of Oslo</institution>, <addr-line>Oslo</addr-line>, <country>Norway</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/943079/overview">Nino Kuenzli</ext-link>, Swiss Tropical and Public Health Institute (Swiss TPH), Switzerland</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Nikola Biller-Andorno, <email>biller-andorno@ibme.uzh.ch</email>
</corresp>
<fn fn-type="other" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>ORCID: Giovanni Spitale, <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0002-6812-0979">orcid.org/0000-0002-6812-0979</ext-link>; Federico Germani, <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0002-5604-0437">orcid.org/0000-0002-5604-0437</ext-link>; Nikola Biller-Andorno, <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0001-7661-1324">orcid.org/0000-0001-7661-1324</ext-link>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>05</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>70</volume>
<elocation-id>1608617</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>04</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>05</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Spitale, Germani and Biller-Andorno.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Spitale, Germani and Biller-Andorno</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<kwd-group>
<kwd>preference epidemiology</kwd>
<kwd>patient-centered care</kwd>
<kwd>health policy</kwd>
<kwd>health literacy</kwd>
<kwd>health communication strategies</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Two pivotal events in 2024 &#x2013; the USPSTF (United States Preventive Services Task Force)&#x2019;s revised recommendations for cancer screening, and the symbolic &#x201c;end of an era&#x201d; for Dartmouth Atlas marked by the passing of Jack Wennberg, alongside shifts in the Center for Medicare and Medicaid Services&#x2019; policies on claims data access &#x2013; underscore the urgent need to reflect on the integration of patient preferences into healthcare decision-making and policy development. Healthcare decisions often demand that individuals weigh the potential benefits of an intervention against possible burdens, risks and harms, a process influenced by personal values, beliefs, and prior experiences. Traditionally, public health policies have focused on population-level evidence on key performance indicators of healthcare practices (such as the number of deaths prevented by such practices) to guide recommendations. However, this approach can overlook the nuanced ways in which individuals process information and make choices, which are not always driven solely by the potential of a healthcare practice to reduce mortality risk. The Dartmouth Atlas has already demonstrated how healthcare practices and outcomes can vary significantly across regions, depending on factors such as practice patterns, physician preferences, resources availability, and patient demographics [<xref ref-type="bibr" rid="B1">1</xref>]. Preference epidemiology offers a framework for understanding how individuals value trade-offs between benefits and burdens, risks, and harms of a certain healthcare practice, paving the way for a more patient-centered approach to healthcare [<xref ref-type="bibr" rid="B2">2</xref>]. Thus, preference epidemiology can determine how benefits and burdens, risks and harms are weighed by people.</p>
<p>Patient decisions on medical treatment are rarely straightforward. Different individuals may understand or respond to the same information in diverse ways, depending on their unique thresholds for risk tolerance, burden or harm acceptance (for themselves or for their families), and their prioritization of benefits, as exemplified in the case of PSA (Prostate Specific Antigen) screening for prostate cancer detection [<xref ref-type="bibr" rid="B3">3</xref>&#x2013;<xref ref-type="bibr" rid="B5">5</xref>]. People&#x2019;s values and past experiences can deeply shape their health choices: for instance, in the case of PSA screening, individuals with a family history of illness may be more inclined to pursue screening tests, while those with previous negative healthcare experiences might hesitate [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>]. Preference epidemiology systematically investigates these factors, shedding light on why individuals may choose certain healthcare options over others. In a similar way, the history of mammography recommendations for breast cancer detection highlights the challenges of communicating nuanced risk-benefit information to the public. Although graded as beneficial by the United States Preventive Services Task Force (USPSTF) in 2002, the recommendation was later modified multiple times (most recently in June 2024) [<xref ref-type="bibr" rid="B6">6</xref>&#x2013;<xref ref-type="bibr" rid="B9">9</xref>], sparking confusion in the US and abroad. A primary concern here is that these recommendations for the integration or use of healthcare practices are based on assumptions regarding their worthiness, without knowing if those concerned&#x2013;the patients and their families &#x2013; would have similarly weighed the benefits, risks, burdens, and potential harms of such practices. These aspects would be considered by preference epidemiology research, leading to tailored, evidence-based recommendations and communication that integrate clinical evidence with evidence on patients&#x2019; diverse values, perceptions, and preferences [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B10">10</xref>].</p>
<p>In the case of screening practices, some patients may value greatly the benefit of an early detection of disease, despite a risk of overdiagnosis or overtreatment, while others may prefer to avoid risking any unnecessary intervention, even at the cost of a delayed diagnosis. Preference epidemiology aims to capture these varied viewpoints, systematically identifying the specific conditions under which individuals find particular interventions acceptable or not. A core goal of preference epidemiology is to determine the thresholds at which individuals find a medical intervention acceptable [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B11">11</xref>], provided that these decisions are informed and autonomous &#x2013; guaranteed by sufficient medical and information literacy. These insights allow healthcare systems to tailor their programs, policies, and communication strategies to better align with the values of target populations, enhancing the population&#x2019;s ability to make informed and autonomous choices, and enhancing the relevance and impact of healthcare offerings.</p>
<p>Preference epidemiology is significant both at the population and individual level: when policymakers understand the acceptability thresholds of different segments of the population, they can design healthcare programs that better resonate with those groups. This alignment increases both the effectiveness and uptake of healthcare services, benefiting individuals and public health as a whole [<xref ref-type="bibr" rid="B2">2</xref>]. Targeted communication is essential for translating medical information into messages that diverse individuals can relate to and understand [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B12">12</xref>], and by identifying how people evaluate trade-offs, preference epidemiology can help shape communication that enhance health literacy and promote informed decision-making. A cornerstone of preference epidemiology is therefore to promote open, transparent dialogue between patients and healthcare providers. When providers understand a patient&#x2019;s perceptions, values, and preferences, they can offer personalized guidance that supports patients in making decisions aligned with both evidence and their own priorities [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B13">13</xref>&#x2013;<xref ref-type="bibr" rid="B15">15</xref>].</p>
<p>The principles of preference epidemiology are applicable across a range of health interventions that require complex decision-making involving trade-offs based on benefits, burdens, risks and harms. This approach emphasizes the importance of aligning healthcare services with the informed and autonomous preferences of the population. This approach can guide patient-centered policies for interventions, e.g., mammography, colonoscopy, or hypertension screening in adolescents. PSA screening has been a focal point for our initial exploration of preference epidemiology due to the complex interplay of factors that influence individual decision-making surrounding this screening test. Additionally, its use at the population level remains controversial due to conflicting recommendations and an uncertain benefit-to-harm ratio [<xref ref-type="bibr" rid="B16">16</xref>&#x2013;<xref ref-type="bibr" rid="B20">20</xref>]. Studies show that individuals often overestimate the benefits of PSA screening, reflecting a gap between perception of PSA screening and clinical data to support its use at the population level [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>]. This discrepancy is particularly evident among individuals with personal or family experiences with cancer: for instance, men with a family history of prostate cancer may favor PSA screening despite the risks of overdiagnosis, prioritizing peace of mind over clinical probabilities [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B13">13</xref>]. In contexts like this, preference epidemiology data can inform policies that not only rely on clinical evidence, but also respect and address patients&#x2019; concerns and expectations, allowing for health policy decisions that consider citizens&#x2019; values, preferences, priorities, and enabling the development of more responsive healthcare communication strategies.</p>
<p>Preference epidemiology represents a largely untapped resource and a shift toward understanding the subjective dimensions of healthcare decision-making. By emphasizing the role of individual values, preferences, and experiences, it enables the development of healthcare policies and communication strategies that are both evidence-based and patient-centered. Methodologically, preference epidemiology must balance quantitative rigor with qualitative depth: it should be quantitative enough to rapidly gather evidence that supports robust, actionable inferences, while remaining qualitative enough to capture the deeper meanings and motivations behind individuals&#x2019; values and choices. As the field advances, its application across diverse health contexts has the tremendous potential to improve health literacy and empower individuals in making informed, autonomous decisions. By setting the agenda and defining the role of preference epidemiology, we aim to help healthcare systems align more closely with the populations they serve, promoting a more responsive and effective public health landscape.</p>
</body>
<back>
<sec sec-type="author-contributions" id="s1">
<title>Author Contributions</title>
<p>All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.</p>
</sec>
<sec sec-type="funding-information" id="s2">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research and/or publication of this article.</p>
</sec>
<sec sec-type="COI-statement" id="s3">
<title>Conflict of Interest</title>
<p>The authors declare that they do not have any conflicts of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s4">
<title>Generative AI Statement</title>
<p>The authors declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="web">
<collab>Dartmouth Atlas of Health Care</collab>. <article-title>Atlases and Reports</article-title> (<year>2024</year>). <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.dartmouthatlas.org/atlases-and-reports/">https://www.dartmouthatlas.org/atlases-and-reports/</ext-link> (Accessed November 28, 2024)</comment>.</citation>
</ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spitale</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Germani</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Biller-Andorno</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Perceptions and Misconceptions of PSA Screening in Switzerland: A Preference Epidemiology Study</article-title>. <comment>medRxiv</comment>. (<year>2024</year>). <pub-id pub-id-type="doi">10.1101/2024.11.06.24316816v1</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Glasziou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rychetnik</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mackenzie</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gardiner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Doust</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Deliberative Democracy and Cancer Screening Consent: A Randomised Control Trial of the Effect of a Community Jury on Men&#x2019;s Knowledge about and Intentions to Participate in PSA Screening</article-title>. <source>BMJ Open</source> (<year>2014</year>) <volume>4</volume>(<issue>12</issue>):<fpage>e005691</fpage>. <pub-id pub-id-type="doi">10.1136/bmjopen-2014-005691</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torta</surname>
<given-names>RGV</given-names>
</name>
<name>
<surname>Munari</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Psychological Aspects of PSA Testing</article-title>. <source>Nat Rev Urol</source> (<year>2009</year>) <volume>6</volume>(<issue>9</issue>):<fpage>513</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1038/nrurol.2009.146</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrante</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>Factors Influencing Men&#x2019;s Decisions Regarding Prostate Cancer Screening: A Qualitative Study</article-title>. <source>J Community Health</source> (<year>2011</year>) <volume>36</volume>(<issue>5</issue>):<fpage>839</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1007/s10900-011-9383-5</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="book">
<collab>United States Preventive Services Taskforce</collab>. <source>Final Recommendation Statement: Screening for Breast Cancer</source> (<year>2024</year>). <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.uspreventiveservicestaskforce.org/uspstf/announcements/final-recommendation-statement-screening-breast-cancer-0">https://www.uspreventiveservicestaskforce.org/uspstf/announcements/final-recommendation-statement-screening-breast-cancer-0</ext-link> (Accessed November 4, 2024)</comment>.</citation>
</ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicholson</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Silverstein</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Barry</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Chelmow</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Coker</surname>
<given-names>TR</given-names>
</name>
<etal/>
</person-group> <article-title>Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement</article-title>. <source>JAMA</source> (<year>2024</year>) <volume>331</volume>(<issue>22</issue>):<fpage>1918</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2024.5534</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lerner</surname>
<given-names>BH</given-names>
</name>
</person-group>. <article-title>Why Isn&#x2019;t There Agreement on When Women Need to Start Getting Mammograms?</article-title> <source>STAT</source> (<year>2024</year>). <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.statnews.com/2024/05/02/breast-cancer-screening-mammogram-women-40s/">https://www.statnews.com/2024/05/02/breast-cancer-screening-mammogram-women-40s/</ext-link> (Accessed November 4, 2024)</comment>.</citation>
</ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trentham-Dietz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Jayasekera</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lowry</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Heckman-Stoddard</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Hampton</surname>
<given-names>JM</given-names>
</name>
<etal/>
</person-group> <article-title>Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force</article-title>. <source>JAMA</source> (<year>2024</year>) <volume>331</volume>(<issue>22</issue>):<fpage>1947</fpage>&#x2013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2023.24766</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biller-Andorno</surname>
<given-names>N</given-names>
</name>
<name>
<surname>J&#xfc;ni</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Abolishing Mammography Screening Programs? A View from the Swiss Medical Board</article-title>. <source>N Engl J Med</source> (<year>2014</year>) <volume>370</volume>(<issue>21</issue>):<fpage>1965</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMp1401875</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Spitale</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Biller-Andorno</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Germani</surname>
<given-names>F</given-names>
</name>
</person-group>. <source>PSA PrEpidemiology: Exploring Public Preferences and Knowledge in PSA Screening for Prostate Cancer in Switzerland</source>. <publisher-name>OSF</publisher-name> (<year>2024</year>). <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://osf.io/bfy7t/">https://osf.io/bfy7t/</ext-link> (Accessed September 27, 2024)</comment>.</citation>
</ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Spitale</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Germani</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Biller-Andorno</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>The PHERCC Matrix</article-title>. <article-title>An Ethical Framework for Planning, Governing, and Evaluating Risk and Crisis Communication in the Context of Public Health Emergencies</article-title>. <source>The American Journal of Bioethics</source> <volume>24</volume>(<issue>4</issue>):<fpage>67</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1080/15265161.2023.2201191</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wallner</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Sarma</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Lieber</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>St. Sauver</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Jacobson</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>McGree</surname>
<given-names>ME</given-names>
</name>
<etal/>
</person-group> <article-title>Psychosocial Factors Associated with an Increased Frequency of Prostate Cancer Screening in Men Ages 40-79: The Olmsted County Study</article-title>. <source>Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol</source> (<year>2008</year>) <volume>17</volume>(<issue>12</issue>):<fpage>3588</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1158/1055-9965.epi-08-0050</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sweetman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Norman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bunstead</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Hopwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Melia</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Feasibility of Familial PSA Screening: Psychosocial Issues and Screening Adherence</article-title>. <source>Br J Cancer</source> (<year>2006</year>) <volume>94</volume>(<issue>4</issue>):<fpage>507</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6602959</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karafillakis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Larson</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Advance</surname>
<given-names>consortium</given-names>
</name>
</person-group>. <article-title>The Benefit of the Doubt or Doubts over Benefits? A Systematic Literature Review of Perceived Risks of Vaccines in European Populations</article-title>. <source>Vaccine</source> (<year>2017</year>) <volume>35</volume>(<issue>37</issue>):<fpage>4840</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.07.061</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="web">
<collab>IQWiG. IQWiG</collab>. <article-title>PSA Screening: Benefit Does Not Outweigh Harm</article-title> (<year>2020</year>). <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.iqwig.de/en/presse/press-releases/press-releases-detailpage_9949.html">https://www.iqwig.de/en/presse/press-releases/press-releases-detailpage_9949.html</ext-link> (Accessed September 27, 2024)</comment>.</citation>
</ref>
<ref id="B17">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schr&#xf6;der</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Hugosson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Roobol</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Tammela</surname>
<given-names>TLJ</given-names>
</name>
<name>
<surname>Zappa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nelen</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group> <article-title>Screening and Prostate Cancer Mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 Years of Follow-Up</article-title>. <source>Lancet Lond Engl</source> (<year>2014</year>) <volume>384</volume>(<issue>9959</issue>):<fpage>2027</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(14)60525-0</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Tangen</surname>
<given-names>CM</given-names>
</name>
</person-group>. <article-title>Prostate Cancer Screening Comes of Age</article-title>. <source>The Lancet</source> (<year>2014</year>) <volume>384</volume>(<issue>9959</issue>):<fpage>2004</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(14)61008-4</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ilic</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Appraising the European Randomized Study of Screening for Prostate Cancer: What Do the Results Mean?</article-title> <source>Asian J Androl</source> (<year>2015</year>) <volume>17</volume>(<issue>2</issue>):<fpage>221</fpage>&#x2013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.4103/1008-682X.142131</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loeb</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bjurlin</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tammela</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Penson</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>HB</given-names>
</name>
<etal/>
</person-group> <article-title>Overdiagnosis and Overtreatment of Prostate Cancer</article-title>. <source>Eur Urol</source> (<year>2014</year>) <volume>65</volume>(<issue>6</issue>):<fpage>1046</fpage>&#x2013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.eururo.2013.12.062</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>